Figure 3.
NRM and relapse by conditioning regimen intensity. (A) The 3-year incidence of NRM adjusted for age, sex, performance score, HCT-CI, diagnosis, and donor type/donor-recipient HLA match was 27% (95% CI, 22-31) for Bu4/Cy, 27% (95% CI, 23-32) for Flu/Bu4, 23% (95% CI, 18-29) for Flu/Bu4 + ATG, 18% (95% CI, 14-22) for Flu/Bu2, 18% (95% CI, 18-24) for Flu/Bu2 + ATG, 27% (95% CI, 21-34) for Flu/Mel, and 27% (95% CI, 18-37) for Flu/Mel + ATG. (B) The 3-year incidence of relapse adjusted for performance score, HCT-CI, diagnosis, disease risk index, and donor type/donor-recipient HLA match was 32% (95% CI, 28- 36) for Bu4/Cy, 32% (95% CI, 27-36) for Flu/Bu4, 41% (95% CI, 34-47) for Flu/Bu4 + ATG, 46% (95% CI, 41-51) for Flu/Bu2, 56% (95% CI, 49-62) for Flu/Bu2 + ATG, 22% (95% CI, 16-28) for Flu/Mel, and 28% (95% CI, 17-41) for Flu/Mel + ATG.

NRM and relapse by conditioning regimen intensity. (A) The 3-year incidence of NRM adjusted for age, sex, performance score, HCT-CI, diagnosis, and donor type/donor-recipient HLA match was 27% (95% CI, 22-31) for Bu4/Cy, 27% (95% CI, 23-32) for Flu/Bu4, 23% (95% CI, 18-29) for Flu/Bu4 + ATG, 18% (95% CI, 14-22) for Flu/Bu2, 18% (95% CI, 18-24) for Flu/Bu2 + ATG, 27% (95% CI, 21-34) for Flu/Mel, and 27% (95% CI, 18-37) for Flu/Mel + ATG. (B) The 3-year incidence of relapse adjusted for performance score, HCT-CI, diagnosis, disease risk index, and donor type/donor-recipient HLA match was 32% (95% CI, 28- 36) for Bu4/Cy, 32% (95% CI, 27-36) for Flu/Bu4, 41% (95% CI, 34-47) for Flu/Bu4 + ATG, 46% (95% CI, 41-51) for Flu/Bu2, 56% (95% CI, 49-62) for Flu/Bu2 + ATG, 22% (95% CI, 16-28) for Flu/Mel, and 28% (95% CI, 17-41) for Flu/Mel + ATG.

Close Modal

or Create an Account

Close Modal
Close Modal